When is the next results date for Medicamen Biotech Ltd?
2026-02-05 23:17:25The next results date for Medicamen Biotech Ltd is scheduled for 13 February 2026....
Read full news article
Medicamen Biotech Ltd is Rated Sell
2026-02-04 10:10:33Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article
Medicamen Biotech Ltd Valuation Shifts Signal Price Attractiveness Challenges
2026-02-03 08:01:07Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen a notable shift in its valuation parameters, moving from fair to expensive territory. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, raises questions about the stock's price attractiveness relative to its historical averages and peer group. Despite a recent uptick in share price, the company’s fundamental scores and returns suggest a cautious approach for investors.
Read full news article
Medicamen Biotech Ltd is Rated Sell
2026-01-24 10:10:03Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 August 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 January 2026, providing investors with the latest insights into the company’s performance and outlook.
Read full news article
Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mild Momentum Shift
2026-01-23 08:01:23Medicamen Biotech Ltd has experienced a nuanced shift in its technical momentum, with several key indicators signalling a transition from bearish to mildly bearish territory. Despite a recent uptick in price, the stock continues to face headwinds amid mixed signals from MACD, RSI, moving averages, and other technical tools, reflecting a complex outlook for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Mildly Bearish Momentum
2026-01-09 08:06:19Medicamen Biotech Ltd, a player in the Pharmaceuticals & Biotechnology sector, is currently exhibiting a nuanced shift in its technical momentum. While some indicators suggest mild bullishness, others point towards a cautious, mildly bearish trend, reflecting a complex market sentiment as the stock trades at ₹400.00, up 1.19% on 9 Jan 2026.
Read full news article
Medicamen Biotech Ltd Shows Mixed Technical Signals Amid Price Momentum Shift
2026-01-08 08:15:00Medicamen Biotech Ltd has experienced a notable shift in price momentum, reflected in a 9.09% gain on 8 Jan 2026, signalling a potential technical turnaround. However, the stock’s broader technical indicators present a complex picture, with mixed signals from MACD, RSI, moving averages and other momentum oscillators, suggesting cautious optimism for investors in the Pharmaceuticals & Biotechnology sector.
Read full news article
Medicamen Biotech Ltd is Rated Sell
2026-01-02 10:10:03Medicamen Biotech Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 12 Aug 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 02 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Read full news article
Medicamen Biotec Sees Revision in Market Assessment Amid Mixed Financial Signals
2025-12-22 10:10:04Medicamen Biotec, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key financial and technical parameters. This adjustment comes amid a backdrop of mixed performance indicators and ongoing challenges in the company’s long-term growth trajectory.
Read full news articleBoard Meeting Intimation for Consideration Of Unaudited Consolidated And Standalone Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2025.
04-Feb-2026 | Source : BSEMedicamen Biotech Ltd-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2026 inter alia to consider and approve the unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended on December 31 2025.
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
16-Jan-2026 | Source : BSECompliance- Certificate under Reg 74 (5) of SEBI (DP) Regulations 2018
Announcement Under Regulation 30 (LODR)- EU Approval For Product Registration Of Paracetamol
07-Jan-2026 | Source : BSEAnnouncement under Regulation 30 (LODR) - EU approval for product registration of Paracetamol from Danish Medicine Authority with XGX Pharma - Denmark
Corporate Actions
13 Feb 2026
Medicamen Biotech Ltd has declared 10% dividend, ex-date: 19 Sep 25
No Splits history available
No Bonus history available
No Rights history available






